ANXA2 and pancreatic neoplasm: In summary, intracellular ANXA2 can directly regulate the transcriptional activity of NF-κB by binding to the p50 subunit of NF-κB, inducing gemcitabine resistance in pancreatic cancer cells through upregulation of anti-apoptotic genes, including that encoding IL-6.